Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking method to diabetes management. These innovative drugs operate by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these agents increase insulin release and inhibit glucagon rel

The management of diabetes has become with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising strategies for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel